Biocytogen

Gene-ius Break Seattle: Just Around the Corner! ?? We’re headed to the Pacific Northwest! Join us, KACTUS and Biocytogen on Wednesday, April 2nd for an evening of food, drinks, and energizing conversations with fellow biotech and biopharma professionals. Whether you’re looking to unwind or spark new collaborations, this is your chance to connect in Seattle’s vibrant life sciences scene. ??? Time: Wednesday, April 2nd · 4:00 PM - 8:00 PM PT ?? Location: Victor Tavern Eastlake, 1600 Eastlake Ave E, Seattle, WA 98102 ??? Bonus: Parking is hassle-free at this location! ?? RSVP here: https://hubs.ly/Q03dW2YX0 Let’s raise a glass to science, connection, and innovation. Make sure to chat with Yujiao ZHANG, PhD & we hope to see you there! #GeneiusBreak #Seattle #Biotech #LifeSciences #KACTUS

Heading to AACR? Stop by Biocytogen’s Booth #4008 and let us know—who are you most excited to meet? ?? Vote in our poll and swing by our booth—we can’t wait to connect! ?? #AACR #Biocytogen #CancerResearch #BiotechNetworking

??Congratulations?to Eric Hatterer and?Julien Montorfani?on your recent publication in the?Journal of Immunotherapy of Cancer! This innovative work on?B-hIL2RB/hIL2RG mice?and the development of a?dual bispecific antibody strategy?to modulate IL2R/IL15R activation marks an exciting advancement in immunotherapy. We are thrilled to see?Biocytogen’s humanized mouse models?supporting cutting-edge discoveries in cancer research. Explore our full catalog here: https://lnkd.in/e7f6d4Aw Looking forward to more breakthroughs through collaboration and innovation!????? #Immunotherapy #BispecificAntibodies #HumanizedMice #Biocytogen #CancerResearch #IL2 #IL15

?? Join Us! Webinar on Preclinical Evaluation Systems for Bispecific Antibodies ?? Bispecific antibodies (bsAbs) are transforming drug development with enhanced specificity, efficacy, and resistance mitigation. Discover how Biocytogen’s cutting-edge in vivo models and pharmacology expertise help advance bsAb translation! ?? Date & Time: Wed, April 16 | 1:00 PM EDT ??? Speaker: Dr. Qiurong Wang, Regional BD Director ?? Register Now: https://lnkd.in/eGjYe5tr ?? Key Takeaways: ? The evolving role of bsAbs in tackling complex diseases like cancer and autoimmune disorders ? How Biocytogen’s innovative in vivo animal models accelerate bsAb therapeutic development ? Challenges, future directions, and what lies ahead in the field #Webinar #BispecificAntibodies #PreclinicalResearch #Biocytogen #DrugDevelopment #CancerTherapy #AutoimmuneDiseases #Innovation #PharmaceuticalResearch #MouseModels #HumanizedMice

?Advancing Respiratory Disease Research with Cutting-Edge Models ???? Respiratory diseases such as asthma, acute lung injury, and COPD impact millions worldwide, highlighting an urgent need for innovative therapies that address disease mechanisms and improve patient outcomes. At Biocytogen, our advanced respiratory disease models—developed using drug target-humanized mice—offer researchers a reliable in vivo platform to evaluate drug efficacy, study disease progression, and accelerate breakthrough therapies in a human-relevant context. Let’s drive innovation in respiratory research together! ??? #Biocytogen #RespiratoryDisease #DrugDiscovery #COPD #Asthma #BiotechInnovation #AcuteLungInjury #HumanizedMice #PreclinicalResearch

?? Celebrating #ScienceAppreciationDay!???? Science has a way of transforming the impossible into reality—like harnessing genetically modified mice to drive breakthrough discoveries! At Biocytogen, we’re all about pushing the boundaries of drug discovery with fully human antibody assets, humanized mouse models, and preclinical solutions that accelerate biomedical research. ?? ????Fun fact with Biocytogen: On April 25th in 1953, the structure of DNA was first published in?Nature, laying the foundation for modern genetics, precision medicine, and even the antibody discovery platforms we use today! What’s a scientific breakthrough that inspires you? Let us know in the comments! ?? #Biocytogen #DrugDiscovery #Innovation #CancerResearch #Immunology #Biotech

Seattle, Thank You for Bringing the Energy to Lunch & Learn! ???? A huge thank you to the incredible researchers, scientists, and biotech professionals who joined us at Seattle Children's Research Institute for an inspiring Lunch & Learn! Your engagement, curiosity, and passion for innovation made this event a great success. From exploring groundbreaking research to exchanging ideas over lunch, it was amazing to witness the power of collaboration in action. We’re excited to continue fostering connections that drive biotech advancements and scientific breakthroughs. Here’s to more learning, networking, and innovation ahead! ?? #LunchAndLearn #Biocytogen #SeattleChildrens #BiotechNetworking #Innovation #DrugDiscovery #Collaboration

Advancing Chronic Disease Treatment with Biocytogen’s Antibody Innovation ??? Over 1.5 billion people worldwide live with chronic diseases like diabetes, COPD, and heart failure—conditions driven by complex biological mechanisms that current therapies often fail to fully address. In diabetes, current treatments often struggle with glycemic control and cardiovascular risks. COPD therapies like bronchodilators and steroids fail to halt disease progression or address immune dysfunction. Heart failure treatments fall short in targeting neurohormonal pathways and cardiac remodeling. At Biocytogen, our RenMice? antibody discovery platforms are advancing the development of fully human antibodies that precisely target disease-driving pathways, restore biological balance, and aim to deliver transformative outcomes. This includes diabetes-related assets like our GLP1R antibody, as well as COPD-related assets such as IGHE antibody, MET VHH antibody, and more. Innovation in antibody therapeutics is shaping the future of chronic disease treatment—let’s drive progress together! ?? ??? #Biocytogen #RenMice #AntibodyTherapeutics #ChronicDisease #DrugDiscovery #Biotech #Diabetes #COPD #HeartFailure?